CriticalFourth-generation fluoroquinolone×Non-selective beta blocker with class III antiarrhythmic activity
Updated · Methodology
Mechanism
Dual QT prolongation. Torsades de pointes.
Symptoms
QTc above 500 ms, syncope, torsades de pointes risk.
Management
Combination contraindicated.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- FDA: Moxifloxacin tablet (Chartwell Rx, LLC) – Prescribing Information – QT prolongation warning (2016)– FDA Avelox label, Warnings and Precautions §5.7 – avoid with QT-prolonging drugs; DailyMed setid 656f582c-ecba-4ec8-9420-9562114d889b
- FDA: Betapace (sotalol) prescribing information – QT and antiarrhythmic interactions (2011)– FDA Betapace label, Contraindications §4 and Warnings §5; DailyMed setid a6a7702f-36c9-45db-b640-453dc324baee
- AEMPS: Ficha técnica: Moxifloxacino (nº registro 74573), sección 4.5 (2026)– AEMPS, CIMA, nº registro 74573, revisión 03/2026, sección 4.5